PAG
PRVB

Private Advisor Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Private Advisor Group’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,707
Closed -$129K – 2282
2022
Q1 		$129K Buy
+17,707
New +$106K ﹤0.01% 1967
2021
Q3 		– Sell
-24,400
Closed -$206K – 2119
2021
Q2 		$206K Buy
+24,400
New +$197K ﹤0.01% 1817
2020
Q4 		– Sell
-10,800
Closed -$139K – 1838
2020
Q3 		$139K Buy
10,800
+4,300
+66% +$54.3K ﹤0.01% 1461
2020
Q2 		$92K Buy
+6,500
New +$82.1K ﹤0.01% 1755

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Private Advisor Group's PRVB Position: Q2 2022 in Review

Private Advisor Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2022, closing a stake of 17,707 shares — an estimated $129K sold.

Private Advisor Group first reported a position in PRVB in Q2 2020 and held it in 4 quarters. The position peaked at $206K in Q2 2021. 115 funds tracked by Wall St. Rank hold PRVB as of Q2 2022.

  • Private Advisor Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Private Advisor Group sold 17,707 Provention Bio, Inc. Common Stock shares in Q2 2022, an estimated $129K.
  • Private Advisor Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Private Advisor Group's Provention Bio, Inc. Common Stock position peaked at $206K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2022.

Based on Private Advisor Group's 13F filing for Q2 2022, filed 13 Jul 2022.